BiotechTube
NanoDx

NanoDx

Providence, United States· Est.
nanodiagnostics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

NanoDx is pioneering a novel point-of-care diagnostic platform that leverages patented nanowire biosensor technology licensed from Harvard University and IBM. The company's core value proposition is enabling rapid, accurate, and multiplexed biomarker detection at the patient's side, aiming to accelerate treatment decisions and reduce healthcare costs. Its lead program targets Traumatic Brain Injury (TBI) and has received FDA Breakthrough Device Designation, positioning it as a potential first-to-market solution. As a private, pre-revenue company, NanoDx is developing an expandable platform with a strategy to address a wide range of future diagnostic applications across various care settings.

Traumatic Brain Injury

Technology Platform

Proprietary nano biosensor platform utilizing patented nanowire technology licensed from Harvard University and semiconductor tech from IBM. Enables rapid, multiplexed detection of biomarkers from a small blood sample at the point of care.

Funding History

2
Total raised:$4.2M
Seed$3M
Grant$1.2M

Opportunities

The global point-of-care diagnostics market offers a large and growing addressable market, with a specific high-need opportunity in objective TBI testing.
The company's versatile platform allows for rapid expansion into additional high-value diagnostic areas like cardiac care and sepsis, creating a pipeline-in-a-platform model.

Risk Factors

Key risks include regulatory uncertainty, as the lead TBI test requires FDA clearance despite its Breakthrough Designation, and the challenge of clinically validating a novel biomarker panel.
The company also faces commercialization and scaling risks as a pre-revenue entity dependent on external funding in a competitive diagnostics landscape.

Competitive Landscape

NanoDx competes in the broad POC diagnostics market dominated by large players like Abbott, Roche, and Siemens Healthineers. In the specific niche of TBI biomarkers, it faces competition from other companies developing blood tests (e.g., Banyan Biomarkers' BTI, Abbott's i-STAT TBI test) and must differentiate through its platform's speed, multiplexing capability, and potential for lower cost per test.

More companies in Diagnostics & Precision Medicine →More companies in United States →